Work

Exposure–response (E–R) analyses of efficacy and safety with raludotatug deruxtecan (R-DXd), a CDH6-directed antibod-drug conjugate (ADC), to inform dose selection for phase (Ph) 3 development in platinum-resistant ovarian cancer (PROC).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.5570

Authors: Felipe K. Hurtado, Emily Schapiro, Elizabeth Lusk, Isabelle Laure Ray-Coquard, Lydia Gaba, Kosei Hasegawa, Alexander Philipovskiy, Izna Ali, Youngjun Yoo, Hiroyuki Inoue, Tsvetomir Mitov, Guillaume Bergthold, Yvonne Lau

Institutions: Daiichi Sankyo (United States), Centre Léon Bérard, Hospital Clínic de Barcelona, Spanish Ovarian Cancer Research Group, Saitama International Medical Center, Saitama Medical University, Florida Cancer Specialists & Research Institute, Daiichi-Sankyo (Japan), Daiichi Sankyo (United Kingdom)

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Daiichi Sankyo Europe

OpenAlex ID: W7162567759

Cites:

Cited by: 1

Related to: